Novartis continues its investments in Lek, a Sandoz company. To date, Novartis invested more than 1.7 billion Euros, half of which was invested in the development and the other half in modernization and expansion of production capabilities.
Lek is a part of Sandoz, the generic division of Novartis, a pioneer in the field of biosimilars and the second-largest generic pharmaceutical company in the world. Our pharmaceutical generic organization operates in Slovenia, Europe, and worldwide. It focuses on connecting with customers and evolving the future. We help secure long-term access to healthcare. We develop, produce and distribute effective, safe and high-quality medicines, ranging from standard generics through modern biosimilar medicines. In 2016 we celebrate 20 years of Novartis, and 70 years of Lek. Together we are the leading supplier of medicines to the Slovenian market.
Lek, a Sandoz company, has been co-creating development trends in the global pharmaceutical industry for 70 years and has been continuously growing. We are a Slovenian, European and global pharmaceutical generic company, people-orientated and future-oriented. With our knowledge, quality and experience we have become one of the key parts of Sandoz.
Verovškova 57, 1526 Ljubljana, Slovenia
T: +386 1 580 21 11
F: +386 1 568 35 17
VAT No.: SI87916452
Registration number: 1732811000
Nominal capital: 48.402.003,00 EUR
Visit the pharmaceutical collection, Slovenian national cultural heritage.